Equities research analysts forecast that Intellia Therapeutics Inc (NASDAQ:NTLA) will report sales of $7.70 million for the current quarter, according to Zacks Investment Research. Four analysts have made estimates for Intellia Therapeutics’ earnings, with the highest sales estimate coming in at $10.63 million and the lowest estimate coming in at $5.00 million. Intellia Therapeutics reported sales of $7.68 million during the same quarter last year, which would suggest a positive year over year growth rate of 0.3%. The business is scheduled to report its next quarterly earnings results on Wednesday, August 7th.
According to Zacks, analysts expect that Intellia Therapeutics will report full year sales of $28.82 million for the current financial year, with estimates ranging from $10.40 million to $42.50 million. For the next year, analysts forecast that the firm will report sales of $31.48 million, with estimates ranging from $20.00 million to $44.40 million. Zacks Investment Research’s sales averages are an average based on a survey of sell-side research analysts that cover Intellia Therapeutics.
Intellia Therapeutics (NASDAQ:NTLA) last posted its earnings results on Thursday, May 2nd. The company reported ($0.49) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.53) by $0.04. The firm had revenue of $10.43 million during the quarter, compared to analyst estimates of $9.43 million. Intellia Therapeutics had a negative net margin of 257.28% and a negative return on equity of 31.68%. Intellia Therapeutics’s revenue was up 39.7% on a year-over-year basis. During the same period in the previous year, the business posted ($0.51) EPS.
A number of research analysts recently commented on the company. BidaskClub raised Intellia Therapeutics from a “hold” rating to a “buy” rating in a research note on Friday, April 5th. Zacks Investment Research downgraded Intellia Therapeutics from a “hold” rating to a “sell” rating in a research note on Tuesday, May 7th. Evercore ISI assumed coverage on Intellia Therapeutics in a research note on Thursday, April 11th. They issued an “outperform” rating for the company. Chardan Capital reaffirmed a “buy” rating and issued a $57.50 price target on shares of Intellia Therapeutics in a research note on Wednesday, February 27th. Finally, Wedbush raised Intellia Therapeutics from a “neutral” rating to an “outperform” rating and boosted their price target for the company from $20.00 to $21.00 in a research note on Friday, May 3rd. One analyst has rated the stock with a sell rating, six have given a hold rating and five have given a buy rating to the company. The company has an average rating of “Hold” and a consensus price target of $29.25.
In related news, EVP Andrew Schiermeier purchased 7,500 shares of the company’s stock in a transaction that occurred on Wednesday, March 6th. The stock was acquired at an average price of $15.72 per share, with a total value of $117,900.00. Following the completion of the purchase, the executive vice president now directly owns 3,250 shares in the company, valued at $51,090. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 4.10% of the stock is owned by insiders.
A number of hedge funds and other institutional investors have recently modified their holdings of the business. We Are One Seven LLC bought a new stake in Intellia Therapeutics in the fourth quarter worth approximately $28,000. Tortoise Investment Management LLC grew its stake in shares of Intellia Therapeutics by 100.0% in the first quarter. Tortoise Investment Management LLC now owns 2,000 shares of the company’s stock valued at $34,000 after buying an additional 1,000 shares in the last quarter. Quantamental Technologies LLC grew its stake in shares of Intellia Therapeutics by 1,170.4% in the first quarter. Quantamental Technologies LLC now owns 3,303 shares of the company’s stock valued at $56,000 after buying an additional 3,043 shares in the last quarter. Patriot Financial Group Insurance Agency LLC grew its stake in shares of Intellia Therapeutics by 35.8% in the fourth quarter. Patriot Financial Group Insurance Agency LLC now owns 5,495 shares of the company’s stock valued at $75,000 after buying an additional 1,450 shares in the last quarter. Finally, Nikko Asset Management Americas Inc. grew its stake in shares of Intellia Therapeutics by 20.0% in the fourth quarter. Nikko Asset Management Americas Inc. now owns 5,980 shares of the company’s stock valued at $82,000 after buying an additional 995 shares in the last quarter. 71.33% of the stock is owned by hedge funds and other institutional investors.
Intellia Therapeutics stock traded up $0.38 during midday trading on Friday, reaching $15.88. 273,423 shares of the stock traded hands, compared to its average volume of 588,386. The company has a quick ratio of 7.74, a current ratio of 7.74 and a debt-to-equity ratio of 0.06. The firm has a market capitalization of $683.84 million, a price-to-earnings ratio of -7.91 and a beta of 2.79. Intellia Therapeutics has a fifty-two week low of $11.03 and a fifty-two week high of $32.95.
Intellia Therapeutics Company Profile
Intellia Therapeutics, Inc, a genome editing company, focuses on the development of therapeutics utilizing a biological tool known as the CRISPR/Cas9 system. The company develops in vivo programs focused on liver diseases, including transthyretin amyloidosis, alpha-1 antitrypsin deficiency, and primary hyperoxaluria.
Featured Story: How prevalent are 12b-1 fees?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Intellia Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intellia Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.